By Michael Gottesman
Monday, May 21, 2018
James F. Holland, M.D., a renowned cancer expert who was a major figure in the development of cancer chemotherapy, died on March 22, 2018, at the age of 92. Dr. Holland was among the first group of research physicians recruited to the NIH Clinical Center, serving as a senior surgeon at the National Cancer Institute from 1953 to 1954. In that short year at the NIH, he initiated a clinical trial to compare continuous or intermittent treatment with two chemotherapy agents for acute leukemia in children: methotrexate and 6-mercaptopurine. Dr. Holland moved to Roswell Park Memorial Institute in Buffalo before the trial was completed, but he continued to collaborate. His work ultimately turned an incurable illness into one with an 80% survival rate. In 1972, he and his NIH collaborators shared the Albert Lasker Clinical Medical Research Award for "outstanding contribution to the concept and application of combination therapy in the treatment of acute leukemia in children."
By IRP Staff Blogger
Monday, June 20, 2016
Terran Dupree, 16, is one of the most positive teenagers you will ever meet. With the brightest smile and the most humbling personality, you would never know that she is fighting a rare form of cancer.
By IRP Staff Blogger
Monday, September 28, 2015
As this LabTV profile of an outstanding nurse-scientist shows, there are many different paths to a career in biomedical research. Leorey Saligan grew up in the Philippines, where the challenges and rewards of caring for sick family members inspired him to become a nurse. His first job was at a nursing home in Midland, TX, and the next at a nearby hospital. Later, Saligan moved to Norfolk, VA, where as a nurse practitioner he began caring for people with sarcoidosis, an inflammatory disease that affects several organ systems.
Read more...
By IRP Staff Blogger
Wednesday, September 16, 2015
A panel of three genetic markers may help to identify patients with early-stage lung cancer who have a very strong likelihood of their disease returning after surgery, according to findings from a study by NCI researchers. Read more...
By Michele Lyons
Friday, February 27, 2015
“Then we have ‘prevention is more important than cure.’ That’s the one I like best. That’s my pet peeve…."
Dr. Emil Freireich, NCI, in his 1997 oral history. Dr. Freireich helped develop combined chemotherapy for childhood leukemia.
